Assenagon Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Assenagon Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.4M	Sell	73,175 -457,443	-86%	-$22M	﹤0.01%	742
2026 Q1	$27.4M	Buy	+530,618	New	+$27M	0.04%	288
2024 Q1	–	Sell	-36,254	Closed	-$1.05M	–	1476
2023 Q4	$1.05M	Buy	+36,254	New	+$961K	﹤0.01%	1082
2023 Q2	–	Sell	-54,889	Closed	-$1.99M	–	1457
2023 Q1	$1.99M	Sell	54,889 -113,121	-67%	-$4.35M	0.01%	837
2022 Q4	$5.99M	Buy	168,010 +125,795	+298%	+$4.37M	0.02%	499
2022 Q3	$1.43M	Hold	42,215	–	–	0.01%	824
2022 Q2	$1.22M	Buy	+42,215	New	+$1.21M	﹤0.01%	1009
2022 Q1	–	Sell	-69,389	Closed	-$2.02M	–	1553
2021 Q4	$2.02M	Buy	+69,389	New	+$2.11M	0.01%	814
2019 Q1	–	Sell	-6,702	Closed	-$223K	–	1110
2018 Q4	$223K	Buy	+6,702	New	+$288K	﹤0.01%	950

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Assenagon Asset Management's SUPN Position: Q2 2026 in Review

Assenagon Asset Management reduced its Supernus Pharmaceuticals (SUPN) stake by 86% in Q2 2026, selling an estimated $22M and leaving 73,175 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #742.

Assenagon Asset Management first reported a position in SUPN in Q4 2018 and has held it in 9 quarters since. The position peaked at $27.4M in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Assenagon Asset Management held 73,175 shares of Supernus Pharmaceuticals worth $3.4M as of Q2 2026.
Assenagon Asset Management sold 457,443 Supernus Pharmaceuticals shares in Q2 2026, an estimated $22M.
Supernus Pharmaceuticals made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #742 holding.
Assenagon Asset Management first reported a position in Supernus Pharmaceuticals in Q4 2018 and has held it in 9 quarters since.
Assenagon Asset Management's Supernus Pharmaceuticals position peaked at $27.4M in Q1 2026.
332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.